Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Sy. Huang,Jiří Minařík,Michele Cavo,H. Miles Prince,Cheng Zheng,Franck Dubin,Helgi van de Velde,Kenneth C. Anderson

Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

2021

Paul G. Richardson
Aurore Perrot
Jesús F. San Miguel
Meral Beksac
Ivan Spicka
Xavier Leleu
Fredrik Schjesvold
Philippe Moreau
Meletios A. Dimopoulos
Jeffrey Sy. Huang
Jiří Minařík
Michele Cavo
H. Miles Prince
Cheng Zheng
Franck Dubin
Helgi van de Velde
Kenneth C. Anderson

8017Background: Isa is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. The Phase 3 ICARIA-MM study (NCT02990338) demonstrated significantly improved progressi...

Keywords:

Epitope
CD38
Isatuximab
Cancer research
Dexamethasone
Receptor
Monoclonal antibody
Medicine
Pomalidomide
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations